SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!

Diagnosis and Management in Parkinson's Disease: The Neuroscience of Parkinson’s, Volume 1 provides a single source of material covering different scientific domains of neurop… Read more
SUSTAINABLE DEVELOPMENT
Save up to 30% on top Physical Sciences & Engineering titles!
Part I: Introductory chapters and setting the scene
1. Progression of symptoms in Parkinson’s diseaseFederico Paolini Paoletti, Lucia Farotti and Lucilla Parnetti
2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson’s disease: an overviewK.F. Loewenbruck, F. Pan-Montojo and H. Reichmann
3. The role of environmental toxins and inflammation in Parkinson’s disease pathophysiology: a historical perspective and research-based evidenceF. Pan-Montojo, K.F. Loewenbruck and H. Reichmann
4. Environmental and genetic risk factors for Parkinson’s diseaseLazaros Belbasis, Vanesa Bellou and Evangelos Evangelou
5. Recent developments in the etiology, treatment, and potential therapeutic targets for Parkinson’s disease: a focus on biochemistrySapana Sameer Chaudhary, Sameer Chaudhary, Sakshi Rawat, Saieswari Natesan, Tanvee Pardeshi, Athanasios Alexiou and Ghulam Md Ashraf
6. Facial emotion recognition in Parkinson’s disease: methodological, clinical, and pathophysiological factorsMarco De Risi, Enrica Olivola, Giancarlo Di Gennaro and Nicola Modugno
7. Diurnal patterns and circadian aspects of Parkinson’s disease: retinal, hypothalamic/midbrain, and pineal participationGregory L. Willis
8. Parkinson’s disease and social mediaIbrahim S. Al-Busaidi and Yassar Alamri
9. Sleep disturbances in Parkinson’s diseasAdriano D.S. Targa, Juliane Fagotti, Patrícia Dominico, Ana Paula Chuproski and Marcelo M.S. Lima
10. Recurrent falls in people with Parkinson’s diseaseLorena Rosa S. Almeida, Serene S. Paul and Guilherme T. Valenca
11. Medical decision-making in patients with Parkinson’s diseaseJanneke Koerts, Josephien Jansen, Anselm B.M. Fuermaier, Lara Tucha and Oliver Tucha
12. Visual impairment in Parkinson’s diseaseAlessandro Arrigo, Alessandro Calamuneri, Emanuela Aragona, Enricomaria Mormina and Michele Gaeta
13. Autonomic problems in Parkinson’s disease: a focus on the bladderRyuji Sakakibara, Fuyuki Tateno, Tatsuya Yamamoto and Tomoyuki Uchiyama
14. Dementia and bladder dysfunction: a focus on treatments with anticholinergicsRyuji Sakakibara and Fuyuki Tateno
15. Linking and comparing non-motor symptoms in aging and Parkinson’s diseasePetra Bago Rozankovic
16. Progression of motor symptoms in Parkinson’s diseaseDaniela Vieira, Joana Jesus-Ribeiro and Cristina Januario
17. The stigma of Parkinson’s disease: development and implications John T.H. Tsiang and Benjamin K.P. Woo
Part II: Biomarkers, instruments, diagnosis and assessments
18. Better neuroradiological approach for the diagnosis of early-stage Parkinson’s disease patientsYasuaki Mizutani, Yoshiki Niimi and Tatsuro Mutoh
19. Use of positron-emission tomography as a diagnostic and differential diagnostic tool in parkinsonian syndromesPetra Tomse, Tomaz Rus, Matej Perovnik, Chris C. Tang, David Eidelberg and Maja Trost
20. Keyboard typing for the detection of early Parkinson’s diseaseWarwick R. Adams
21. Cerebrospinal fluid biomarkers of Parkinson’s disease: an updateKanae Nagao and Peter A. LeWitt
22. Understanding Parkinson’s disease pathophysiology: clinical application of eye movement tasks and underlying neural correlatesKikuro Fukushima, Junko Fukushima and Graham R. Barnes
23. Measuring quality of life in Parkinson’s diseaseMaria Jo~ao Forjaz, Carmen Rodríguez-Blazquez and Pablo MartinezeMartin
24. Clinically assessing cognitive function in Parkinson’s diseaseMegan Bakeberg, Maddeson Riley, Michelle Byrnes, Frank L. Mastaglia and Ryan S. Anderton
Part III: Pharmacological treatments, other agents and strategies
25. A new neuroprotective strategy for the drug therapy of Parkinson’s disease: Ca2þ/cAMP signaling as therapeutic targetsAfonso Caricati-Neto, Fulvio Alexandre Scorza and Leandro Bueno Bergantin
26. Dopamine agonists in treatment of Parkinson’s disease: an overviewDan Luo, Maarten Reith and Aloke K. Dutta
27. Management with apomorphine in Parkinson’s diseaseManon Auffret, Sophie Drapier and Marc Verin
28. Management with monoamine oxidase B inhibitors in Parkinson’s diseaseThomas Muller
29. Management with antibiotics in Parkinson’s diseaseMariza Bortolanza, Bruno L. Santos-Lobato, Glauce Crivelaro Nascimento and Elaine Del-Bel
30. Intracerebroventricular administration of dopamine in Parkinson’s disease: treatment of motor fluctuations and dyskinesiaC. Laloux, C. Lachaud, C. Moreau, M. Fisichella, J.C. Devedjian, J.A. Duce and D. Devos
31. Placebo and nocebo responses in Parkinson’s diseaseFabrizio Benedetti, Elisa Carlino, Elisa Frisaldi, Alessandro Piedimonte, Maurizio Zibetti, Michele Lanotte and Leonardo Lopiano
32. Levodopa-induced dyskinesias in Parkinson’s diseaseStephanie L. Alberico and Nandakumar S. Narayanan
33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s diseaseMiguel A. Abellanas and Maria S. Aymerich
Part IV: Non-pharmacological, novel and other treatment procedures
34. Deep brain stimulation surgery in Parkinson’s diseaseLee Neilson, Jonathan Zande and Hesham Abboud
35. Gene delivery for Parkinson’s diseasePiotr Chmielarz, Anne Panhelainen, Mikko Airavaara and Andrii Domanskyi
36. Cell transplantation therapy for Parkinson’s diseasePiotr Chmielarz, Julia Konovalova and Andrii Domanskyi
37. Ursodeoxycholic and tauroursodeoxycholic acids as antiapoptotic agents: modulation of Parkinson’s diseaseNoha F. Abdelkader
38. Interlinking potential therapy with botulinum neurotoxin-A and Parkinson’s diseaseAndreas Wree, Alexander Hawlitschka, Carsten Holzmann, Martin Witt, Jens Kurth, Tobias Lindner, Teresa Mann and Veronica Antipova
39. Neuropeptide cocaine- and amphetamine-regulated transcript usage in Parkinson’s diseasePeizhong Mao and Yifan Mao
40. Photobiomodulation as a neuroprotective strategy for Parkinson’s diseaseClaudia Petrucco, Patrick Benson, Luke Gordon, Jonathan Stone and Daniel M. Johnstone
41. Assistive technologies in Parkinson’s diseaseRoongroj Bhidayasiri
Index
CR
VP